Last reviewed · How we verify
Leu-Met-Sil 1.0
At a glance
| Generic name | Leu-Met-Sil 1.0 |
|---|---|
| Also known as | NS-0200-1.0 |
| Sponsor | NuSirt Biopharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity (PHASE2)
- The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leu-Met-Sil 1.0 CI brief — competitive landscape report
- Leu-Met-Sil 1.0 updates RSS · CI watch RSS
- NuSirt Biopharma portfolio CI